Please ensure Javascript is enabled for purposes of website accessibility

Why Reata Pharmaceuticals Stock Is Plunging Today

By Prosper Junior Bakiny – Aug 10, 2020 at 11:26AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The clinical-stage drug company may not be able to file for FDA approval of a top candidate as soon as expected.

What happened?

Shares of Reata Pharmaceuticals (RETA -8.06%) were down by about 32% as of 12:21 p.m. EDT on Monday after the company released its second-quarter earnings report before the market opened. The financial results weren't the big story, however: In the update, the company said that its regulatory filing for Omaveloxolone, one of its leading pipeline candidates, could be delayed. 

So what

Omaveloxolone is a potential treatment for Friedreich's Ataxia (FA), a rare genetic disorder that causes difficulty walking and impaired speech. Following a successful phase 2 clinical trial, the results of which Reata Pharmaceuticals announced in October, the company had planned to submit the drug to the U.S. Food and Drug Administration for marketing approval. However, the FDA isn't confident that those phase 2 results will support a marketing authorization for Omaveloxolone. 

Road sign that says "risk ahead."

Image source: Getty Images.

The regulator may request that Reata Pharmaceuticals conduct another clinical trial, which could be a serious problem. Running a clinical study for FA is a challenging endeavor because the disease is rare and it progresses slowly, two factors that make it hard to find trial participants. The COVID-19 pandemic would render the task even more difficult. Thus, the need to conduct an additional trial for Omaveloxolone would significantly delay any potential approval of the drug, which explains why investors are selling off shares of Reata Pharmaceuticals. 

Now what

Reata Pharmaceuticals proposed that it conduct a crossover study that would test the efficacy of Omaveloxolone on patients who were previously randomized into the placebo arm of the phase 2 study, and who are currently taking the drug in the open-label extension of the study. Pending approval of that plan by the FDA, the company said it could finish the crossover study by year's end.

If, however, the FDA does not accept this proposal -- or if the data from that study proves inconclusive -- the healthcare company will have to conduct another clinical trial. Given the uncertainty associated with Omaveloxolone, and considering Reata Pharmaceuticals currently has no approved drugs on the market, investors might want to watch this one unfold from a safe distance, at least for now. 

Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Reata Pharmaceuticals, Inc. Stock Quote
Reata Pharmaceuticals, Inc.
RETA
$22.12 (-8.06%) $-1.94

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
329%
 
S&P 500 Returns
106%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/25/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.